{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:37:22Z","timestamp":1785796642783,"version":"3.56.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"am","delay-in-days":277,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejmech.2025.117595","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T04:28:30Z","timestamp":1743740910000},"page":"117595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Discovery of the first-in-class DOT1L PROTAC degrader"],"prefix":"10.1016","volume":"291","author":[{"given":"Hyerin","family":"Yim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renhong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huen Suk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. \u00dcmit","family":"Kaniskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-3862","authenticated-orcid":false,"given":"Jian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"41","key":"10.1016\/j.ejmech.2025.117595_bib1","doi-asserted-by":"crossref","first-page":"43296","DOI":"10.1074\/jbc.M405902200","article-title":"Structure of the conserved core of the yeast Dot1p, a nucleosomal histone H3 lysine 79 methyltransferase","volume":"279","author":"Sawada","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117595_bib2","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0960-9822(02)00901-6","article-title":"Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain","volume":"12","author":"Feng","year":"2002","journal-title":"Curr. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117595_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1534\/genetics.104.033191","article-title":"Characterization of the grappa gene, the Drosophila histone H3 lysine 79 methyltransferase","volume":"169","author":"Shanower","year":"2005","journal-title":"Genetics"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117595_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0092-8674(03)00114-4","article-title":"Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase","volume":"112","author":"Min","year":"2003","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117595_bib5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0092-8674(02)00759-6","article-title":"Dot1p modulates silencing in yeast by methylation of the nucleosome core","volume":"109","author":"van Leeuwen","year":"2002","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117595_bib6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00412-015-0570-5","article-title":"The upstreams and downstreams of H3K79 methylation by DOT1L","volume":"125","author":"Vlaming","year":"2016","journal-title":"Chromosoma"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117595_bib7","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1158\/0008-5472.CAN-16-1663","article-title":"The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription","volume":"77","author":"Wong","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117595_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41375-020-0808-y","article-title":"H3K79me2\/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1\/CD133 in MLL-AF4 leukemia cells","volume":"35","author":"Godfrey","year":"2021","journal-title":"Leukemia"},{"issue":"47","key":"10.1016\/j.ejmech.2025.117595_bib9","doi-asserted-by":"crossref","first-page":"39698","DOI":"10.1074\/jbc.M112.384057","article-title":"Human histone H3K79 methyltransferase DOT1L protein [corrected] binds actively transcribing RNA polymerase II to regulate gene expression","volume":"287","author":"Kim","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117595_bib10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1101\/gad.1198204","article-title":"The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote","volume":"18","author":"Schubeler","year":"2004","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117595_bib11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4161\/cc.28104","article-title":"The histone methyltransferase Dot1\/DOT1L as a critical regulator of the cell cycle","volume":"13","author":"Kim","year":"2014","journal-title":"Cell Cycle"},{"issue":"10","key":"10.1016\/j.ejmech.2025.117595_bib12","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1091\/mbc.11.10.3601","article-title":"Role for the silencing protein Dot1 in meiotic checkpoint control","volume":"11","author":"San-Segundo","year":"2000","journal-title":"Mol. Biol. Cell"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117595_bib13","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/emboj.2012.50","article-title":"Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1\/G2 cell-cycle phases","volume":"31","author":"Wakeman","year":"2012","journal-title":"EMBO J."},{"issue":"7015","key":"10.1016\/j.ejmech.2025.117595_bib14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature03114","article-title":"Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks","volume":"432","author":"Huyen","year":"2004","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ejmech.2025.117595_bib15","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.1074\/jbc.M414453200","article-title":"The DNA damage checkpoint response requires histone H2B ubiquitination by Rad6-Bre1 and H3 methylation by Dot1","volume":"280","author":"Giannattasio","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117595_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000190","article-title":"The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure","volume":"4","author":"Jones","year":"2008","journal-title":"PLoS Genet."},{"issue":"19","key":"10.1016\/j.ejmech.2025.117595_bib17","doi-asserted-by":"crossref","first-page":"10272","DOI":"10.1093\/cercor\/bhad281","article-title":"DOT1L deletion impairs the development of cortical parvalbumin-expressing interneurons","volume":"33","author":"Cheffer","year":"2023","journal-title":"Cerebr. Cortex"},{"issue":"6494","key":"10.1016\/j.ejmech.2025.117595_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/371221a0","article-title":"An early haematopoietic defect in mice lacking the transcription factor GATA-2","volume":"371","author":"Tsai","year":"1994","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.ejmech.2025.117595_bib19","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1182\/blood-2010-12-327668","article-title":"Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation","volume":"117","author":"Jo","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117595_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cell.2005.02.020","article-title":"hDOT1L links histone methylation to leukemogenesis","volume":"121","author":"Okada","year":"2005","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ejmech.2025.117595_bib21","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.molmed.2004.08.005","article-title":"MLL: a histone methyltransferase disrupted in leukemia","volume":"10","author":"Hess","year":"2004","journal-title":"Trends Mol. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117595_bib22","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117595_bib23","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/febs.16605","article-title":"DOT1L regulates MTDH-mediated angiogenesis in triple-negative breast cancer: intermediacy of NF-\u03baB-HIF1\u03b1 axis","volume":"290","author":"Neeli","year":"2023","journal-title":"FEBS J."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117595_bib24","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1158\/1078-0432.CCR-21-1299","article-title":"DOT1L is a novel cancer stem cell target for triple-negative breast cancer","volume":"28","author":"Kurani","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117595_bib25","doi-asserted-by":"crossref","first-page":"eaav5590","DOI":"10.1126\/sciadv.aav5590","article-title":"Inhibition of histone methyltransferase DOT1L silences ERalpha gene and blocks proliferation of antiestrogen-resistant breast cancer cells","volume":"5","author":"Nassa","year":"2019","journal-title":"Sci. Adv."},{"issue":"13","key":"10.1016\/j.ejmech.2025.117595_bib26","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2012-11-465120","article-title":"Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l","volume":"121","author":"Deshpande","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117595_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.ejmech.2025.117595_bib28","doi-asserted-by":"crossref","first-page":"11367","DOI":"10.1158\/0008-5472.CAN-05-1041","article-title":"Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications","volume":"65","author":"Milne","year":"2005","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117595_bib29","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1101\/gad.1898410","article-title":"Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom)","volume":"24","author":"Mohan","year":"2010","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117595_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-022-01251-1","article-title":"Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias","volume":"15","author":"Yi","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"24","key":"10.1016\/j.ejmech.2025.117595_bib31","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1101\/gad.1741408","article-title":"Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia","volume":"22","author":"Guenther","year":"2008","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117595_bib32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","article-title":"MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L","volume":"20","author":"Bernt","year":"2011","journal-title":"Cancer Cell"},{"issue":"27","key":"10.1016\/j.ejmech.2025.117595_bib33","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2106148118","article-title":"DOT1L complex regulates transcriptional initiation in human erythroleukemic cells","volume":"118","author":"Wu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"44","key":"10.1016\/j.ejmech.2025.117595_bib34","doi-asserted-by":"crossref","first-page":"27365","DOI":"10.1073\/pnas.2001075117","article-title":"DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation","volume":"117","author":"Cao","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.117595_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.917125","article-title":"The role of DOT1L in normal and malignant hematopoiesis","volume":"10","author":"Arnold","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117595_bib36","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1021\/acs.chemrev.6b00801","article-title":"Inhibitors of protein methyltransferases and demethylases","volume":"118","author":"Kaniskan","year":"2018","journal-title":"Chem. Rev."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117595_bib37","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1124\/jpet.114.214577","article-title":"DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells","volume":"350","author":"Klaus","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2025.117595_bib38","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ncomms2304","article-title":"Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors","volume":"3","author":"Yu","year":"2012","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117595_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117595_bib40","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1021\/acsmedchemlett.9b00452","article-title":"New potent DOT1L inhibitors for in vivo evaluation in mouse","volume":"10","author":"Stauffer","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117595_bib41","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117595_bib42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/bdd.1889","article-title":"Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor","volume":"35","author":"Basavapathruni","year":"2014","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.ejmech.2025.117595_bib43","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-121926","article-title":"A Phase Ib\/II study of the histone methyltransferase inhibitor pinometostat in combination with azacitidine in patients with 11q23-rearranged acute myeloid leukemia","volume":"134","author":"Menghrajani","year":"2019","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ejmech.2025.117595_bib44","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117595_bib45","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/cbdd.12050","article-title":"Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L","volume":"80","author":"Basavapathruni","year":"2012","journal-title":"Chem. Biol. Drug Des."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117595_bib46","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117595_bib47","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117595_bib48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117595_bib49","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"6241","key":"10.1016\/j.ejmech.2025.117595_bib50","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.ejmech.2025.117595_bib51","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1039\/D3CS00100H","article-title":"Chemically induced degradation of epigenetic targets","volume":"52","author":"Kabir","year":"2023","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117595_bib52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.117595_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128653","article-title":"Targeting epigenetic modulators using PROTAC degraders: current status and future perspective","volume":"63","author":"Webb","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117595_bib54","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1021\/acs.jmedchem.2c00345","article-title":"Exploring degradation of mutant and wild-type epidermal growth factor receptors induced by proteolysis-targeting chimeras","volume":"65","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2025.117595_bib55","doi-asserted-by":"crossref","first-page":"8657","DOI":"10.1021\/jm5011258","article-title":"Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities","volume":"57","author":"Galdeano","year":"2014","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2025.117595_bib56","doi-asserted-by":"crossref","first-page":"18054","DOI":"10.1021\/acs.jmedchem.1c01476","article-title":"Design, synthesis, and evaluation of potent, selective, and bioavailable AKT kinase degraders","volume":"64","author":"Yu","year":"2021","journal-title":"J. Med. Chem."},{"issue":"7239","key":"10.1016\/j.ejmech.2025.117595_bib57","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"issue":"7753","key":"10.1016\/j.ejmech.2025.117595_bib58","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","article-title":"Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens","volume":"568","author":"Behan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117595_bib59","series-title":"Protein Tyrosine Kinase 6 (Ptk6) Degradation\/Disruption Compounds and Methods of Use","author":"Jin","year":"2020"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425003605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425003605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:52:12Z","timestamp":1778043132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425003605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":59,"alternative-id":["S0223523425003605"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117595","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of the first-in-class DOT1L PROTAC degrader","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117595"}}